Company Description
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer.
Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology.
The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer.
Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer.
The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Country | United States |
| Founded | 1982 |
| IPO Date | Jan 1, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. Amit Kumar Ph.D. |
Contact Details
Address: 3150 Almaden Expressway, Suite 250 San Jose, California 95118 United States | |
| Phone | 408-708-9808 |
| Website | anixa.com |
Stock Details
| Ticker Symbol | ANIX |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0000715446 |
| CUSIP Number | 03528H109 |
| ISIN Number | US03528H1095 |
| Employer ID | 11-2622630 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Amit Kumar Ph.D. | Chief Executive Officer, Chairman and Co-Chair of CBAB |
| Michael J. Catelani CPA, MBA | President, Chief Operating Officer, Chief Financial Officer and Corporate Secretary |
| John Roop | Senior Vice President of Engineering |
| Dr. Pamela D. Garzone Ph.D. | Chief Development Officer and Chair Breast Cancer Clinical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| May 3, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 10-Q | Quarterly Report |
| Feb 8, 2024 | DEF 14A | Other definitive proxy statements |
| Jan 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 16, 2024 | 10-K | Annual Report |
| Dec 7, 2023 | 8-K | Current Report |